98%
921
2 minutes
20
Introduction: Employees considering participation in workplace genetic and/or genomic testing (wGT) as part of workplace wellness programs should be aware of legal protections of their personal genetic information. Given the relevance of the Health Insurance Portability and Accountability Act (HIPAA) and the Genetic Information Nondiscrimination Act (GINA) for informed decision-making, employers offering wGT should ideally inform employees of these health policies prior to collecting any genetic data. It is unclear, however, whether and to what extent such information is being provided. Company websites provide one important resource for making employees - and the public at large - aware of important health policies governing workplace wellness programs in general, and wGT services in particular.
Method: We systematically reviewed the websites of 420 companies (including 140 privately held companies from the 2019 Forbes list of largest privately held companies, 140 publicly held companies from the 2019 Forbes list of largest publicly held companies, 104 hospitals/hospital systems, and 36 companies that had evidence that they offer/have offered wGT) offering wGT services to determine if they included reference to HIPAA and GINA.
Results: Our search for wGT programs on company websites found that 50 of 420 companies had evidence of offering wGT. We found 32/50 (64%) mentions of HIPAA and no mentions of GINA.
Conclusions: It is imperative that HIPAA and GINA are upheld by both vendors and employers. Accessible and understandable information on these policies is needed for employees to analyze the benefits and risks of participating in wGT.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000546189 | DOI Listing |
J Am Acad Orthop Surg
September 2025
From the University of Texas Health Science Center at Houston, Houston, Texas (Osadebey), University of South Carolina School of Medicine, Greenville, South Carolina, Sports Medicine and Shoulder Reconstruction at Prisma Health (Pill), Department of Orthopedic Surgery at Stanford University, Redwood
Management of acromioclavicular separations remains controversial. A variety of surgical techniques have been described, but no clear consensus has formed regarding optimal treatment. As these techniques have evolved, so have the complication profiles.
View Article and Find Full Text PDFBiosens Bioelectron
September 2025
Department of Biological Sciences, Faculty of Science, National University of Singapore, 117543, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore; Precision Medicine Translational Research Programme (TRP), Yong Loo Lin School
DNAzymes possessing kinase-like activities have long held theoretical promise, yet their practical implementation has remained significantly limited. Notably, DNAzyme kinase 1 (DK1), discovered over two decades ago, exhibits a unique self-phosphorylation capability upon encountering specific substrates like ATP, but its broad-based and programmable applications have not yet been fully realized. In this study, we innovatively couple DK1's autophosphorylation mechanism with the PfAgo to establish a novel programmable cascade sensing platform named RASTEN (Robust pfAgo-based Strategy for POC Testing Non-nucleic Acid and Nucleic Acid).
View Article and Find Full Text PDFEpilepsy Behav
September 2025
University of Plymouth, Plymouth PL4 8AA, UK; CIDER, Cornwall Partnership NHS Foundation Trust Truro TR4 9LD, UK.
Background: Epilepsy is prevalent in 22.2% of the intellectual disability (ID) population, with complexities spanning across health and social care sectors. Minimal research has been conducted to explore the experiences of epilepsy care within social care, despite its significance.
View Article and Find Full Text PDFNat Med
September 2025
GenOmics and Translational Research Center, RTI International, Research Triangle Park, NC, USA.
Although genomic sequencing presents groundbreaking newborn screening (NBS) opportunities, critical feasibility and utility questions remain. Here we present initial results from the Early Check program-an observational study assessing the feasibility and clinical utility of genomic NBS in North Carolina. Recruitment was statewide through mailed letters with electronic consent.
View Article and Find Full Text PDFESMO Open
September 2025
Sarah Cannon Research Institute United Kingdom, London, UK. Electronic address:
Background: Antibody-drug conjugates (ADCs) combine targeted monoclonal antibodies with cytotoxic payloads and are an emerging modality in systemic cancer therapy. Thirteen ADCs are Food and Drug Administration approved, with many more in development. However, design and use remain challenging, with issues including on/off-target toxicity, resistance from prior exposure to payload classes, and optimal target/payload selection.
View Article and Find Full Text PDF